Skip to Content
Biotechnology

Is $850,000 for a Blindness Treatment Worth It?

January 3, 2018

Spark Therapeutics, which makes the therapy, today announced the whopping price tag. Called Luxturna, it was approved by the FDA in December, but Spark didn’t disclose the price at the time.

Now it has. And it’s a lot.

In a class of its own. The only approved gene therapy for an inherited type of blindness will cost $425,000 per eye—the most expensive single dose of a drug in the U.S. At $850,000 for both eyes, that would be more than 10 times the median net worth of an American family.

Who will benefit? The therapy is meant to restore eyesight in people who have a specific genetic mutation that causes degeneration of the retina. Spark hasn’t said how many people that is, but by our own estimates, it may be fewer than 30 patients a year.

Is it worth it? While the therapy does stop patients’ eyesight from getting worse and even restores some sight, it’s not a cure, and no one is sure how long the effects last. By contrast, a gene therapy on the market in Europe, called Strimvelis, effectively cures patients with a rare type of immune deficiency for the low, low price of $714,000.

Deep Dive

Biotechnology

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Workers disinfect the street outside Shijiazhuang Railway Station
Workers disinfect the street outside Shijiazhuang Railway Station

Why China is still obsessed with disinfecting everything

Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.